Vecuronium: Pharmacology and Clinical Use

Quick Answer

Vecuronium is an intermediate-acting aminosteroid non-depolarizing neuromuscular blocker. Structure: Steroid nucleus with quaternary ammonium groups (bisquaternary). Mechanism: Competitive antagonist at nicotinic acetylcholine receptors (α subunits) of neuromuscular junction. Pharmacokinetics: Hepatic metabolism (deacetylation by liver esterases) to active metabolites (3-desacetylvecuronium - 80% potency, 17-desacetylvecuronium - 50% potency), renal excretion of metabolites. Dose: 0.08-0.1 mg/kg (intubation), ED95 0.05 mg/kg. Onset: 3-4 minutes. Duration: 25-40 minutes (clinical). Cardiovascular: Minimal (no histamine release, no ganglionic blockade, no vagolytic effects). Elimination: 30-40% unchanged in bile, 30-40% renal, remainder hepatic metabolism. Active metabolites: Accumulate in renal failure (prolonged block). Reversal: Neostigmine (0.05 mg/kg) or sugammadex (preferred - 2 mg/kg for moderate, 4 mg/kg for deep block). Advantage: Hemodynamic stability. Contraindications: None specific (relative caution in renal/hepatic failure due to accumulation). [1-10]

Pharmacology

Chemical Structure

Class:

• Aminosteroid (pregnane nucleus, like rocuronium and pancuronium)
• Bisquaternary ammonium compound: Two charged nitrogen groups
• Molecular weight: 638 Da (bromide salt)
• Structure similarity: 2-desacetyl analogue of pancuronium (less potent, shorter acting than pancuronium)

Physical Properties:

• Form: Lyophilized powder (must be reconstituted)
• Reconstitution: Sterile water or 0.9% saline (10 mg in 5 mL = 2 mg/mL)
• Stability: Refrigerated 2-8°C (stable 24 hours at room temperature after reconstitution)
• pH: 4.0-4.5 (acidic)

Comparison with Pancuronium:

• Vecuronium: 2-desacetyl derivative of pancuronium
• Less potent, shorter acting
• No vagolytic effect (pancuronium blocks cardiac muscarinic receptors → tachycardia)
• No histamine release
• More hemodynamic stability

Mechanism of Action

Neuromuscular Junction:

• Competitive antagonist: Binds to nicotinic acetylcholine receptors on postsynaptic membrane
• Binding site: α subunits (competes with acetylcholine)
• No depolarization: Does not activate receptor (unlike succinylcholine)
• Competitive block: Can be overcome by increasing acetylcholine concentration (anticholinesterases) or waiting for drug elimination

Prejunctional Effect:

• Some blockade of prejunctional nicotinic receptors
• May contribute to "fade" phenomenon with tetanic stimulation (train-of-four)
• Reduces acetylcholine release during repetitive stimulation

Reversibility:

• Competitive antagonism: Can be reversed
• Neostigmine: Inhibits acetylcholinesterase → increased acetylcholine → overcomes block
• Sugammadex: Encapsulates vecuronium (aminosteroid) → inactivates drug
• Spontaneous recovery: Metabolism and elimination

Pharmacokinetics

Administration:

• IV only: Not orally active (charged, poorly absorbed)
• IM: Not recommended (erratic absorption)

Distribution:

• Volume of distribution (Vd): 0.2-0.3 L/kg (ECF volume, hydrophilic)
• Protein binding: 30-50% (albumin and gamma globulin)
• Distribution half-life (t½α): 2-4 minutes (rapid)
• Blood-brain barrier: Does not cross (charged, hydrophilic)
• Placental barrier: Minimal transfer (charged)
• Redistribution: Limited (hydrophilic, stays in ECF)

Metabolism:

• Primary site: Liver (hepatic esterases)
• Pathway: Deacetylation at 3-position and 17-position
• Active metabolites:
  • 3-desacetylvecuronium: 80% potency of parent drug
  • 17-desacetylvecuronium: 50% potency of parent drug
  • 3,17-bisdesacetylvecuronium: Minimal activity
• Significance of metabolites:
  • Contribute to prolonged block in hepatic/renal failure
  • 3-desacetyl is major concern (high potency, accumulates)

Elimination:

• Routes:
  • Biliary: 30-40% unchanged drug
  • Renal: 30-40% unchanged drug + metabolites
  • Metabolism: 20-30% converted to active metabolites
• Clearance: 3-5 mL/kg/min
• Elimination half-life (t½β): 60-80 minutes (long terminal half-life due to slow elimination of metabolites)
• Clinical duration: 25-40 minutes (determined by redistribution and elimination)

Factors Affecting Pharmacokinetics:

Organ Dysfunction:

• Hepatic failure:
  • Reduced clearance (↓metabolism, ↓biliary excretion)
  • Prolonged duration
  • Active metabolite accumulation
  • Dose reduction 20-50%
• Renal failure:
  • Reduced clearance of metabolites (accumulation)
  • Prolonged duration
  • Dose reduction 20-50%
• Biliary obstruction:
  • Reduced biliary excretion
  • May slightly prolong effect

Age:

• Neonates/infants:
  • Larger Vd (higher dose mg/kg needed)
  • Immature hepatic metabolism (prolonged effect)
  • Sensitive to NMBs
• Elderly:
  • Reduced clearance (↓hepatic/renal function)
  • Prolonged duration
  • Dose reduction

Obesity:

• Dosing: Lean body weight (hydrophilic, doesn't distribute to fat)
• Caution: May need higher absolute dose but same mg/kg based on LBW

Drug Interactions:

• Potentiation (increased block):
  • Volatile anaesthetics (halothane > enflurane > isoflurane > sevoflurane/desflurane)
  • Aminoglycoside antibiotics (gentamicin, tobramycin)
  • Clindamycin, polymyxin B
  • Magnesium sulfate
  • Local anaesthetics (procaine, lidocaine)
  • Calcium channel blockers
  • Lithium
  • Quinine
• Antagonism (reduced block):
  • Calcium salts (increase ACh release)
  • Phenytoin, carbamazepine (chronic use - enzyme induction)
  • Corticosteroids (chronic use)

Pharmacodynamics

Dose-Response:

• ED95: 0.05 mg/kg (dose producing 95% suppression of twitch response)
• Intubating dose: 0.08-0.1 mg/kg (1.5-2× ED95)
• Maintenance: 0.01-0.02 mg/kg (15-20 minutes)
• Infusion: 1-2 μg/kg/min (0.06-0.12 mg/kg/hour)

Onset:

• Time to maximum block: 3-4 minutes (0.1 mg/kg dose)
• Intubating conditions: At 3-4 minutes (adequate block)
• Factors affecting onset:
  • Dose (higher = faster)
  • Cardiac output (higher CO = faster onset)
  • Muscle group (orbicularis oculi faster than adductor pollicis)

Duration:

• Clinical duration: 25-40 minutes (T1 recovery to 25%)
• 95% recovery: 60-90 minutes (T4/T1 ratio >0.9)
• Factors affecting duration:
  • Dose (higher = longer)
  • Organ function (impaired = prolonged)
  • Potentiating drugs (volatiles, aminoglycosides)
  • Temperature (hypothermia prolongs)
  • Age (elderly prolonged)

Recovery:

• Spontaneous: 60-90 minutes to TOF ratio >0.9
• With neostigmine: 30-40 minutes (if T1 recovery to 25% before reversal)
• With sugammadex: 2-3 minutes (moderate block), 3-5 minutes (deep block)

Cardiovascular Effects:

• Heart rate: No change (unlike pancuronium which causes tachycardia)
  • No vagolytic effect (does not block cardiac muscarinic receptors)
  • No ganglionic blockade
• Blood pressure: Minimal change
  • No histamine release
  • No sympathetic stimulation
• Hemodynamic stability: One of its main advantages
• Arrhythmias: Rare

Other Effects:

• Histamine release: None (unlike atracurium, mivacurium)
• Ganglionic blockade: None
• Vagal blockade: None (does not cause tachycardia)
• ICP: No effect (does not cross BBB)
• IOP: No effect
• Placental transfer: Minimal (does not affect fetus)
• Autonomic effects: None

Comparison with Other Non-Depolarizing Relaxants:

Clinical Use

Indications

Primary Uses:

1. Muscle relaxation for surgery: General surgical procedures (abdominal, thoracic, orthopaedic)
2. Intubation: When rapid sequence not required (slower onset than rocuronium/sux)
3. Mechanical ventilation: ICU (long-term infusions - caution due to accumulation)
4. Procedures requiring immobility: Laparoscopy, ophthalmic surgery

Specific Advantages:

• Hemodynamic stability: No tachycardia, no hypotension
• No histamine release: Safe for asthmatics, allergy-prone patients
• Intermediate duration: Suitable for most procedures 30-90 minutes
• Reversible: With sugammadex or neostigmine

Contraindications and Cautions

Absolute Contraindications:

• None specific (safe drug profile)
• Allergy: Previous anaphylaxis to vecuronium or other aminosteroids (possible cross-reactivity)

Relative Contraindications/Cautions:

• Severe renal failure: Active metabolite accumulation (3-desacetylvecuronium)
  • Prolonged block possible
  • Consider alternative (cisatracurium)
  • If used: Reduce dose, allow longer recovery time
• Severe hepatic failure: Reduced metabolism and biliary excretion
  • Prolonged block
  • Dose reduction
• Myasthenia gravis: Extreme sensitivity (upregulated receptors)
  • Reduce dose 90%
  • Monitor closely with TOF
• Elderly: Prolonged duration (reduce dose)
• Hypothermia: Prolonged duration (slows metabolism)

Administration

Intubation:

• Dose: 0.08-0.1 mg/kg IV bolus
• Timing: Wait 3-4 minutes for maximum effect
• Monitoring: Train-of-four (confirm adequate block - 0-1 twitches)
• Adjuncts: Adequate anaesthesia (NMB does not prevent awareness)

Maintenance:

• Redosing: 0.01-0.02 mg/kg (20-30% of intubating dose)
• Frequency: Every 15-25 minutes (when T1 recovers to 25%)
• Infusion: 1-2 μg/kg/min (0.06-0.12 mg/kg/hour)
  • Titrate to TOF (1-2 twitches)
  • Suitable for long cases
  • Monitor for accumulation (especially >2 hours)

Monitoring:

• Train-of-four (TOF): Essential
  • Quantitative monitor (objective) preferred over subjective
  • Intubation: <10% T1 suppression
  • Maintenance: 1-2 twitches visible
  • Reversal: T4/T1 ratio >0.9 before extubation
• Clinical: 5-second head lift, tongue protrusion, hand grip
• Timing: Last dose 30-40 minutes before planned emergence (may avoid reversal)

Reversal

Sugammadex (Preferred):

• Mechanism: Encapsulation (binds aminosteroids in 1:1 ratio)
• Dose:
  • Moderate block (TOF count 1-2): 2 mg/kg
  • Deep block (PTC 1-2, no twitches): 4 mg/kg
  • Immediate reversal (3 minutes post-intubation): 16 mg/kg
• Onset: 2-3 minutes (TOF ratio >0.9)
• Advantages:
  • Rapid, reliable
  • No cholinergic side effects (unlike neostigmine)
  • Works at any depth (if adequate dose)
• Cautions:
  • Not for benzylisoquinoliniums (atracurium, cisatracurium)
  • Renal excretion (avoid if eGFR <30 mL/min for deep block reversal)
  • Steroid binding (may interfere with hormonal contraceptives - rare)

Neostigmine:

• Mechanism: Anticholinesterase (increases acetylcholine)
• Dose: 0.05 mg/kg (max 5 mg) with glycopyrrolate 0.01 mg/kg or atropine 0.02 mg/kg
• Timing: When T1 has recovered to 25% (2-3 twitches on TOF)
• Onset: 7-10 minutes
• Duration: 30-60 minutes reversal
• Side effects:
  • Bradycardia (prevent with anticholinergic)
  • Salivation, bronchospasm
  • Nausea/vomiting
  • Abdominal cramps
• Maximum dose: 5 mg (higher doses increase side effects without better reversal)

Spontaneous Recovery:

• Option: If adequate time since last dose
• Timing: Last dose 40-60 minutes before emergence
• Monitoring: Confirm TOF ratio >0.9 before extubation
• Advantage: Avoids reversal drug side effects

Special Clinical Scenarios

Renal Failure:

• Caution: Active metabolite (3-desacetylvecuronium) accumulates
• Effect: Prolonged block
• Alternative: Cisatracurium (Hofmann elimination, safe in renal failure)
• If vecuronium used:
  • Reduce dose 50%
  • Allow extra time for recovery
  • Use sugammadex for reversal (not renally cleared)
  • Monitor TOF closely

Hepatic Failure:

• Caution: Reduced metabolism and biliary excretion
• Effect: Prolonged block
• Alternative: Cisatracurium
• If vecuronium used: Reduce dose, prolonged monitoring

Long Cases (>3 hours):

• Accumulation: Context-sensitive half-time increases
• Strategy:
  • Use infusion rather than boluses
  • Stop infusion 40-60 minutes before end
  • Allow spontaneous recovery or use sugammadex
• Risk: "Stacking" of doses if repeated boluses given without adequate recovery

Myasthenia Gravis:

• Sensitivity: 10× normal sensitivity
• Dose: 0.005-0.01 mg/kg (10% of normal)
• Monitoring: Essential TOF monitoring
• Alternative: Consider cisatracurium (shorter, predictable)

ICU Use:

• Infusion: 1-2 μg/kg/min
• Duration: Days if needed
• Accumulation: Significant (active metabolites)
• Monitoring: Daily TOF, stop q24h to assess recovery
• Alternative: Cisatracurium (no accumulation in organ failure)
• Caution: Critical illness myopathy/polyneuropathy (prolonged NMB may contribute)

Cardiac Surgery:

• Advantage: Hemodynamic stability
• Dose: Standard (0.1 mg/kg)
• CPB: Heats drug, but effect manageable
• Reversal: Sugammadex preferred (fast, reliable)

Laparoscopic Surgery:

• Requirement: Adequate relaxation (pneumoperitoneum)
• Dose: 0.08-0.1 mg/kg then infusion or boluses
• Monitoring: TOF essential (ensure adequate block)

ANZCA Primary Exam Focus

Key Concepts

Structure:

• Aminosteroid (pregnane nucleus)
• Bisquaternary ammonium compound
• 2-desacetyl analogue of pancuronium

Pharmacokinetics:

• Hepatic metabolism (deacetylation) to active metabolites
• 30-40% biliary excretion unchanged
• 30-40% renal excretion
• Active metabolites accumulate in renal failure (3-desacetylvecuronium - 80% potency)

Clinical:

• Intermediate duration (25-40 minutes)
• ED95 0.05 mg/kg
• Intubating dose 0.08-0.1 mg/kg
• Onset 3-4 minutes (not for RSI)
• Hemodynamically stable (no histamine, no vagolytic effect)

Elimination:

• Liver (metabolism to active metabolites)
• Kidneys (excretion of metabolites and some unchanged drug)
• Biliary (excretion of unchanged drug)

Reversal:

• Sugammadex: Encapsulation (preferred, rapid)
• Neostigmine: Anticholinesterase (requires some spontaneous recovery first)

Common Exam Questions

"Compare vecuronium and rocuronium."

• Vecuronium: Less potent (ED95 0.05 mg/kg), slower onset (3-4 min), similar duration (25-40 min), hemodynamically stable, active metabolites accumulate in renal failure, reversed with sugammadex or neostigmine
• Rocuronium: Less potent (ED95 0.3 mg/kg), faster onset (1-2 min), similar duration (30-45 min), hemodynamically stable, minimal active metabolites, reversed with sugammadex (encapsulation) or neostigmine

"Why should vecuronium be used with caution in renal failure?"

• Metabolized to active metabolites (3-desacetylvecuronium with 80% potency)
• Metabolites renally excreted
• Accumulate in renal failure
• Cause prolonged neuromuscular blockade
• Consider alternative (cisatracurium - safe in renal failure)

"What are the advantages of vecuronium over pancuronium?"

• Shorter duration (intermediate vs long-acting)
• No vagolytic effect (no tachycardia - pancuronium blocks cardiac muscarinic receptors)
• No histamine release
• More hemodynamic stability
• Faster recovery

"How is vecuronium metabolized?"

• Hepatic deacetylation by liver esterases
• Forms active metabolites (3-desacetyl and 17-desacetylvecuronium)
• Metabolites excreted in bile and urine
• 30-40% unchanged drug also excreted in bile and urine

"When can neostigmine be given to reverse vecuronium?"

• Must wait until T1 has recovered to 25% (2-3 twitches on TOF visible)
• If given too early: Ineffective reversal, may paradoxically worsen block (desensitization)
• Dose: 0.05 mg/kg with anticholinergic
• Sugammadex alternative: Can be given at any depth (dose-dependent: 2 mg/kg moderate block, 4 mg/kg deep block)

References

1. ANZCA. Primary Examination Syllabus. Pharmacology Section.
2. Agoston S et al. The pharmacokinetics of vecuronium bromide. Eur J Anaesthesiol Suppl. 1986;3:55-65.
3. Bencini AF et al. Hepatobiliary disposition of vecuronium bromide. Anesthesiology. 1986;64(5):515-518.
4. Caldwell JE et al. The pharmacodynamics and pharmacokinetics of vecuronium in patients with and without renal failure. Anesthesiology. 1989;70(1):3-8.
5. Lyman DP et al. Pharmacokinetics of 3-desacetylvecuronium in the elderly. Can J Anaesth. 1993;40(12):1130-1134.
6. Kahwaji R et al. Vecuronium: Drug information. In: UpToDate. 2023.
7. Naguib M et al. Pharmacology of neuromuscular blocking drugs. In: Miller RD (ed). Miller's Anesthesia. 9th ed. Elsevier; 2020:439-468.
8. Hunter JM. New neuromuscular blocking drugs. N Engl J Med. 1995;332(24):1691-1699.